Related Experiment Video
Updated: May 3, 2026

Experimental Approaches to Tissue Engineering
Published on: August 30, 2007
Future therapies: Early trials and basic science
1Professor, Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC.
Abstract:
Pharmacotherapeutic options for overactive bladder (OAB) include antimuscarinics and the beta3-adrenoceptor agonist mirabegron. Research and development of novel therapeutic options for OAB continues to be an active field. This review summarizes recent research with the existing therapies as well as the most promising agents in development.
Insights
Current overactive bladder (OAB) treatments include antimuscarinics and mirabegron. This review covers recent advancements in existing OAB therapies and promising new drug candidates.
Area of Science:
- Urology
- Pharmacology
- Drug Development
Background:
- Overactive bladder (OAB) significantly impacts quality of life.
- Current pharmacotherapies for OAB include antimuscarinics and beta3-adrenoceptor agonists like mirabegron.
Purpose of the Study:
- To review recent research on established OAB treatments.
- To highlight promising novel therapeutic agents currently in development for OAB.
Main Methods:
- Literature review of recent pharmacological research.
- Analysis of clinical trial data for emerging OAB therapies.
Main Results:
- Recent studies show continued efficacy and safety profiles for existing OAB medications.
- Several novel agents targeting different pathways show promise in early-stage development.
Conclusions:
- Ongoing research is refining existing OAB treatments.
- New therapeutic avenues are emerging for managing overactive bladder symptoms.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Microorganisms in Medicine and Therapeutics
Preclinical Development: Overview
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

